CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Work Plus Naltrexone Contingencycombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00684775
NCT00684775Phase 2Completed
CompareCT.gov

Employment-Based Depot Naltrexone Clinical Trial II

Johns Hopkins University·interventional·Posted May 28, 2008·Updated Jan 23, 2018

In Brief

A Phase 2 clinical trial evaluating Work Plus Naltrexone Contingency for Opiate Dependence. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether employment-based naltrexone treatment proves effective in promoting depot naltrexone adherence and drug abstinence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpiate Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 28, 2008
Enrollment StartMay 1, 2008
Primary CompletionApr 30, 2010
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 18.1 years ago

Interventions

Work Plus Naltrexone Contingencycombination

Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the "Work Plus Naltrexone Contingency" condition earned access to working and earning salary by taking depot naltrexone injections once per month.